CDH1 and carcinoma: The absence of E-cad immunostaining (score 0) was observed in three cases (three diffuse type carcinomas), affecting more than 90% of the tumor area (Figure 3D), but in ten cases (one intestinal type and nine diffuse-type carcinomas), negative areas for E-cad were also noted.